Microcephalic osteodysplastic primordial dwarfism type II

Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) is a condition characterized by short stature (dwarfism) with other skeletal abnormalities (osteodysplasia) and an unusually small head size (microcephaly). The growth problems in MOPDII are primordial, meaning they begin before birth, with affected individuals showing slow prenatal growth (intrauterine growth retardation). After birth, affected individuals continue to grow at a very slow rate. The final adult height of people with this condition ranges from 20 inches to 40 inches. Other skeletal abnormalities in MOPDII include abnormal development of the hip joints (hip dysplasia), thinning of the bones in the arms and legs, an abnormal side-to-side curvature of the spine (scoliosis), and shortened wrist bones. In people with MOPDII head growth slows over time; affected individuals have an adult brain size comparable to that of a 3-month-old infant. However, intellectual development is typically normal.

People with this condition have a high-pitched, nasal voice and some have a narrowing of the voicebox (subglottic stenosis). Facial features characteristic of MOPDII include a prominent nose, full cheeks, a long midface, and a small jaw. Other signs and symptoms seen in some people with MOPDII include small teeth (microdontia) and farsightedness. Over time, affected individuals may develop areas of abnormally light or dark skin coloring (pigmentation).

Many individuals with MOPDII have blood vessel abnormalities. For example, some affected individuals develop a bulge in one of the blood vessels at the center of the brain (intracranial aneurysm). These aneurysms are dangerous because they can burst, causing bleeding within the brain. Some affected individuals have Moyamoya disease, in which arteries at the base of the brain are narrowed, leading to restricted blood flow. These vascular abnormalities are often treatable, though they increase the risk of stroke and reduce the life expectancy of affected individuals.

Frequency

MOPDII appears to be a rare condition, although its prevalence is unknown.

Genetic Changes

Mutations in the $PCNT$ gene cause MOPDII. The $PCNT$ gene provides instructions for making a protein called pericentrin. Within cells, this protein is located in structures called centrosomes. Centrosomes play a role in cell division and the assembly of microtubules. Microtubules are fibers that help cells maintain their shape, assist in the process of cell division, and are essential for the transport of materials within cells. Pericentrin acts as an anchoring protein, securing other proteins to the centrosome. Through its interactions with these proteins, pericentrin plays a role in regulation of
the cell cycle, which is the cell’s way of replicating itself in an organized, step-by-step fashion.

*PCNT* gene mutations lead to the production of a nonfunctional pericentrin protein that cannot anchor other proteins to the centrosome. As a result, centrosomes cannot properly assemble microtubules, leading to disruption of the cell cycle and cell division. Impaired cell division causes a reduction in cell production, while disruption of the cell cycle can lead to cell death. This overall reduction in the number of cells leads to short bones, microcephaly, and the other signs and symptoms of MOPDII.

**Inheritance Pattern**

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

**Other Names for This Condition**

- Majewski osteodysplastic primordial dwarfism type II
- MOPD2
- MOPDII
- osteodysplastic primordial dwarfism type II

**Diagnosis & Management**

**Genetic Testing**


**General Information from MedlinePlus**

- Diagnostic Tests [https://medlineplus.gov/diagnostictests.html](https://medlineplus.gov/diagnostictests.html)
- Drug Therapy [https://medlineplus.gov/drugtherapy.html](https://medlineplus.gov/drugtherapy.html)
- Genetic Counseling [https://medlineplus.gov/geneticcounseling.html](https://medlineplus.gov/geneticcounseling.html)
- Palliative Care [https://medlineplus.gov/palliativecare.html](https://medlineplus.gov/palliativecare.html)
- Surgery and Rehabilitation [https://medlineplus.gov/surgeryandrehabilitation.html](https://medlineplus.gov/surgeryandrehabilitation.html)
Patient Support and Advocacy Resources

- Little People of America
  http://www.lpaonline.org
- Little People UK
  http://littlepeopleuk.org/
- Potentials Foundation
  http://www.potentialsfoundation.org/
- The MAGIC Foundation
  https://www.magicfoundation.org/
- Walking with Giants

ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22microcephalic+osteodysplastic+primordial+dwarfism+type+II%22

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28microcephalic+osteodysplastic+primordial+dwarfism+type+II%5BTIAB%5D%29+OR+%28majewski+osteodysplastic+primordial+dwarfism+type+II%5BTIAB%5D%29+OR+%28mopdII%5BTIAB%5D%29+OR+osteodysplastic+primordial+dwarfism+type+II%5BTIAB%5D%29+OR+osteodysplastic+primordial+dwarfism+type+II%5BTIAB%5D%29+OR+mopdII%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D

OMIM

- MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II
  http://omim.org/entry/210720

Sources for This Summary


  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18174396

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19643772

Reprinted from Genetics Home Reference:

Reviewed: February 2018
Published: June 19, 2018

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services